Autopsy report · NCT01305239
A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients
Cause of deathNo reason given
“See termination reason in detailed description.”
Life of this trial
- Registered 2 years 4 months after it had already started.
- Ran for about 2 years 7 months before it stopped.
- 398 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Sponsor
- Pfizer
- Sponsor type
- Industry
- Conditions
- Breast Cancer
- Interventions
- Aromasin
- Participants
- 398
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.